» Articles » PMID: 35454804

Histone Deacetylase Inhibitors Impair Glioblastoma Cell Motility and Proliferation

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Apr 23
PMID 35454804
Authors
Affiliations
Soon will be listed here.
Abstract

Despite being subjected to high-dose chemo and radiotherapy, glioblastoma (GBM) patients still encounter almost inevitable relapse, due to the capability of tumor cells to disseminate and invade normal brain tissues. Moreover, the presence of a cancer stem cell (CSC) subpopulation, already demonstrated to better resist and evade treatments, further frustrates potential therapeutic approaches. In this context, we previously demonstrated that GBM is characterized by a tightly-regulated balance between the β-catenin cofactors TCF1 and TCF4, with high levels of TCF4 responsible for sustaining CSC in these tumors; thus, supporting their aggressive features. Since histone deacetylase inhibitors (HDI) have been reported to strongly reduce TCF4 levels in colon cancer cells, we hypothesized that they could also exert a similar therapeutic action in GBM. Here, we treated primary GBM cultures with Trichostatin-A and Vorinostat, demonstrating their ability to strongly suppress the Wnt-dependent pathways; thus, promoting CSC differentiation and concomitantly impairing GBM cell viability and proliferation. More interestingly, analysis of their molecular effects suggested a prominent HDI action against GBM cell motility/migration, which we demonstrated to rely on the inhibition of the RhoA-GTPase and interferon intracellular cascades. Our results suggest HDI as potential therapeutic agents in GBM, through their action on multiple cancer hallmarks.

Citing Articles

The Role of HDAC6 in Glioblastoma Multiforme: A New Avenue to Therapeutic Interventions?.

Spallotta F, Illi B Biomedicines. 2024; 12(11).

PMID: 39595195 PMC: 11591585. DOI: 10.3390/biomedicines12112631.


A Review of Therapeutic Agents Given by Convection-Enhanced Delivery for Adult Glioblastoma.

Rolfe N, Dadario N, Canoll P, Bruce J Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204078 PMC: 11357193. DOI: 10.3390/ph17080973.


A high-throughput microfabricated platform for rapid quantification of metastatic potential.

Bhattacharya S, Ettela A, Haydak J, Hobson C, Stern A, Yoo M Sci Adv. 2024; 10(33):eadk0015.

PMID: 39151003 PMC: 11328906. DOI: 10.1126/sciadv.adk0015.


Preclinical and clinical advances to overcome hypoxia in glioblastoma multiforme.

Bou-Gharios J, Noel G, Burckel H Cell Death Dis. 2024; 15(7):503.

PMID: 39003252 PMC: 11246422. DOI: 10.1038/s41419-024-06904-2.


On the effects of 30.5 GHz sinusoidal wave exposure on glioblastoma organoids.

Rampazzo E, Persano L, Karim N, Hodgking G, Pinto R, Casciati A Front Oncol. 2024; 14:1307516.

PMID: 38884089 PMC: 11176452. DOI: 10.3389/fonc.2024.1307516.


References
1.
Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

2.
Maretto S, Cordenonsi M, Dupont S, Braghetta P, Broccoli V, Hassan A . Mapping Wnt/beta-catenin signaling during mouse development and in colorectal tumors. Proc Natl Acad Sci U S A. 2003; 100(6):3299-304. PMC: 152286. DOI: 10.1073/pnas.0434590100. View

3.
Persano L, Pistollato F, Rampazzo E, Della Puppa A, Abbadi S, Frasson C . BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression. Cell Death Dis. 2012; 3:e412. PMC: 3481140. DOI: 10.1038/cddis.2012.153. View

4.
Bliss E, WARTH P, LONG P . Studies of combinations of antibiotics in vitro and in experimental infections in mice. Bull Johns Hopkins Hosp. 1952; 90(2):149-69. View

5.
Rampazzo E, Della Puppa A, Frasson C, Battilana G, Bianco S, Scienza R . Phenotypic and functional characterization of Glioblastoma cancer stem cells identified through 5-aminolevulinic acid-assisted surgery [corrected]. J Neurooncol. 2014; 116(3):505-13. DOI: 10.1007/s11060-013-1348-3. View